Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
KAT6B
REST API REST API
Homo sapiens
KAT6B is differentially expressed in 341 experiments: 131 organism parts: bone marrow, ovary, ... (129 more);, 212 disease states: normal, glioblastoma, ... (210 more);, 86 cell types 364 cell lines 52 compound treatments and 81 other conditions.
Synonyms qkf, MOZ2, Morf, querkopf, MYST4
Orthologs RGD1566399 (Rattus norvegicus)   Myst4 (Mus musculus)   ENSCING00000008187 (Ciona intestinalis)   KAT6B (Danio rerio)   ENSGALG00000005035 (Gallus gallus)   KAT6B (Bos taurus)   ESA1 (Saccharomyces cerevisiae)   enok (Drosophila melanogaster)   KAT6B (Canis familiaris)   ENSGALG00000023992 (Gallus gallus)   (Compare orthologs)
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, histone acetyltransferase activity, regulation of transcription, DNA-dependent, acetyltransferase activity, transferase activity, transferring acyl groups other than amino-acyl groups, metal ion binding, transcription factor binding, nucleus, histone acetylation, nucleosome, histone H3 acetylation, chromatin modification, positive regulation of transcription, DNA-dependent, nucleosome assembly, zinc ion binding, MOZ/MORF histone acetyltransferase complex
InterPro Term Histone_H1/H5, Znf_PHD-finger, Znf_PHD, MOZ_SAS
UniProt Accession Q8WYB5, Q69YR9
Search EB-eye ENSG00000156650
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, E-MTAB-62, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (46 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-20081, E-GEOD-3529, E-GEOD-19639
PC3
3
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
BT-474
2
E-GEOD-3529, E-GEOD-5823
SW480
2
E-GEOD-18005, E-MEXP-1014
MDA-MB-231
1
2
E-GEOD-5823, E-TABM-420, E-MTAB-62
CA46
1
E-MTAB-37
358 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-13987, E-GEOD-11755, ... (45 experiments)

Factor Value U/D Experiments
macrophage
3
E-GEOD-22373, E-GEOD-3982, E-GEOD-8286
epithelial cell
2
E-GEOD-4483, E-MEXP-2034
CD105+ endothelial
1
2
E-TABM-145, E-AFMX-5
CD8+ T cell
2
E-AFMX-5, E-TABM-145
mononuclear
2
E-GEOD-13987, E-GEOD-26672
cancer cell culture
1
E-GEOD-14990
80 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-TABM-15, E-MEXP-2280, E-GEOD-16363, ... (72 experiments)

Factor Value U/D Experiments
glioblastoma
1
4
E-GEOD-4290, E-GEOD-4412, E-MTAB-62, E-MTAB-37, E-MEXP-567 ... (5 experiments)
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-2514
melanoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-7307
hepatocellular carcinoma
2
E-MTAB-62, E-MTAB-37
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
obesity
2
E-MTAB-62, E-GEOD-2508
206 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5741, E-GEOD-1417, E-TABM-782, ... (35 experiments)

Factor Value U/D Experiments
none
4
9
E-GEOD-20719, E-GEOD-5824, E-TABM-868, E-GEOD-412, E-GEOD-1417, ... (13 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
valproic acid
1
E-GEOD-1615
AMP
1
1
E-MEXP-2285
water
1
E-MEXP-1372
DMSO
1
1
E-MEXP-1561
46 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
GTE6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-19246, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363, ... (13 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-2666, E-GEOD-4667, E-MEXP-958, ... (6 experiments)

Disease staging
studied in E-GEOD-19743, E-MTAB-69, E-GEOD-21138, E-GEOD-1751, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-17385, ... (7 experiments)

Genotype
studied in E-TABM-763, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-2292, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-22278, E-GEOD-10315, E-MEXP-1273, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (36 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (8 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-MEXP-2177

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

Processing time: 0.489 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM